Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled, Multicenter Phase II Clinical Research of Toripalimab (PD-1 Inhibitor) and Endostar Combined With Radiotherapy and Chemotherapy in the Treatment of High-risk Locally Advanced Nasopharyngeal Carcinoma

Next Previous
Trial Profile

Randomized Controlled, Multicenter Phase II Clinical Research of Toripalimab (PD-1 Inhibitor) and Endostar Combined With Radiotherapy and Chemotherapy in the Treatment of High-risk Locally Advanced Nasopharyngeal Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Endostatin (Primary) ; Gemcitabine (Primary) ; Ropidoxuridine (Primary) ; Toripalimab (Primary)
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Primary endpoint (progression-free survival, PFS) has been met, according to results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 04 Jun 2024 Status changed to completed, according to results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 04 Jun 2024 Results (n=106; From September 7, 2020, to August 23, 2022) assessing the efficacy and safety of adding Toripalimab and Endostar to IC-CCRT in patients with high-risk LA-NPC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top